Government Authorises BioNTech Vaccine

"); jQuery("#212 h3").html("

Related News Programmes

"); });

2021-01-25 HKT 23:57

Share this story

facebook

  • A million doses are expected to arrive in the second half of next month. Photo: Reuters

    A million doses are expected to arrive in the second half of next month. Photo: Reuters

The government on Monday confirmed that it had accepted a recommendation from its expert panel on vaccines to approve a jab made by Germany's BioNTech, and distributed by the mainland's Fosun Pharma.

It's the first vaccine approved for use in the SAR and a million doses are expected to arrive in the second half of next month.

The government had originally planned to give elderly care home residents the coronavirus vaccines produced by mainland company Sinovac. But the Sinovac jabs could not be delivered on time, leaving the authorities with no choice but to use the BioNTech vaccine, which was recommended by an expert panel earlier this month for emergency use.

Earlier this month, Norway flagged up some possible concerns about giving the BioNTech vaccine to very frail and elderly people, following over 20 deaths. The country, though, has reportedly not changed its guidelines on the vaccine.

In a statement on Monday, the government said it was aware of the concerns and asked for more information.

"The Advisory Panel also noted reports of suspected adverse events in some overseas countries after administration of the Fosun Pharma/BioNTech vaccine. According to the information released by the relevant authorities, some common side effects of the vaccines, such as fever or nausea, may affect individuals who already have serious illnesses and are particularly weak.

"In response to the recommendations of the Advisory Panel, the Department of Health has requested the vaccine supplier to provide the relevant information," it said.

The BioNTech vaccine is a new type of vaccine that use messenger ribonucleic acid, or mRNA. This is a type of genetic code that instructs the body to make the spiked part of the Covid-19 virus, which in turn tricks the body into creating antibodies that can fight the real virus.

The Sinovac vaccine is more traditional in nature, using a deactivated virus to produce an immune response.

In addition to BioNTech and Sinovac, the SAR government has also ordered a vaccine jointly developed by Oxford University and Anglo-Swedish pharmaceutical giant AstraZeneca.

The Oxford vaccine is different again. It has been produced from a chimpanzee common cold virus that has been rendered harmless but with genetic information from Covid-19 added into it to bring about antibody production.

RECENT NEWS

Hong Kong Launches Smart Seniors Anti-Scam Ambassador Programme To Protect The Elderly

The Hong Kong Monetary Authority (HKMA) and the Hong Kong Association of Banks (HKAB) jointly organised the launch cere... Read more

Payment Connect Sees Active Participation In Cross-Boundary Remittances

The People’s Bank of China (PBoC) and the Hong Kong Monetary Authority (HKMA) officially launched Payment Connect on ... Read more

GoTyme Hong Kong Is Entering The Scene With Flexible Financing

GoTyme Hong Kong, which is part of the GoTyme Merchant Cash Advance (MCA) Asia business line under Tyme Group, announce... Read more

BGE Is Hong Kongs Latest Licensed Virtual Asset Trading Platform

Hong Kong BGE Limited (BGE) has secured its license to operate as a virtual asset trading platform (VATP) as of 17 June... Read more

China Backs Digital Yuan And Promotes Multi-Polar Currency System

The head of China’s central bank has promised to boost the global adoption of the digital yuan and called for the dev... Read more

JD Targets Stablecoin Licenses In Multiple Markets For Faster Payments

JD.com plans to secure stablecoin licenses in a series of major markets, founder Richard Liu announced at a Beijing pre... Read more